ClinicalTrials.gg
CompletedNCT01469156Updated Dec 12, 2022Results posted

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

A Phase 1/2 interventional study of ranibizumab 0.5 or 2.0 mg/0.05 cc in Polypoidal Choroidal Vasculopathy, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-12.

Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Polypoidal Choroidal Vasculopathy · United States.

Enrollment
3rd of 12
20 · median 20
Started
2011
with 1 other
Phase 1/2
5 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
3 of 13
Southeast Retina Center, Georgia

Among the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 1/2, and was the 7th registered.

Polypoidal Choroidal Vasculopathy

55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.

Browse Polypoidal Choroidal Vasculopathy studies →

Open to participants now

1 of the 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Polypoidal Choroidal Vasculopathy with a site in United States, or all of them as a file.
02

Study summary

This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month of drug safety follow up in subjects with exudative polypoidal choroidal vasculopathy (PCV) for a total of 24 months.

Read the detailed description

Twenty eyes will be randomized will receive 3 consecutive monthly intravitreal 1.0 or 2.0 mg/0.5mg (3:1 ratio) Ranibizumab injection with the first injection occuring at Day 0 and second and third injection occuring at month 1 and month 2 respectively. Retreatment with intravitreal Ranibizumab or other therapies will be at the investigators discretion but guidelines for recommended retreatment.

03

Conditions studied

  • Polypoidal Choroidal Vasculopathy

Keywords

  • polypoidal choroidal vasculopathy
  • choroidal neovascularization
  • ranibizumab
  • Lucentis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females >18 years of age. Females of child bearing potential will undergo urine pregnancy testing and be required to use appropriate methods of .
  • ICG and fluorescein angiographic characteristics consistent with active, leaking PCV with subfoveal lesions and/or subfoveal hemorrhage, lipid exudates, PED or fluid diagnosed within the past 6 months or diagnosed as newly active within the past 6 months. Subjects who completed the 24 month follow up in the original FVF3671s protocol may enter the study without necessarily demonstrating active exudative PCV at enrollment.
  • Best-Corrected ETDRS Visual Acuity at 4 meters between 20/20 - 20/800.
  • Lesion size - no limitations.
  • Lesions Characteristics - leaking lesions consistent with PCV. No limitations on hemorrhage, fibrosis or atrophy.
  • No therapy (includes non foveal laser, PDT, intravitreal , TTT, radiotherapy, or anti-VEGF therapy) or intraocular surgery within the past 30 days for any condition.
  • Clear ocular media to allow for photography/angiography.
  • Ability to provide written and comply with study assessments for the full duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with features of age related macular degeneration such as abundant drusen and demographic features consistent with this diagnosis.
  • Allergy to Fluorescein, ICG, Iodine, Shellfish.
  • Pregnancy (positive pregnancy test)
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the therapy were initiated.
  • Participation in another simultaneous medical investigation or trial.
  • Exclude other anti-VEGF agents as therapy options.
  • History of previous subfoveal laser.
  • Advanced glaucoma (IOP > 25 or cup/disc ration > 0.8)
  • Any condition in the opinion of the investigator that would interfere with disease status/progression or jeopardize patients' participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)

    Intraocular injection of 1.0 or 2.0 mg/0.05 cc ranibizumab. Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met

    Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc

  • Active comparator
    Ranibizumab 0.5 mg

    Intraocular injection of 0.5 mg/0.05 cc ranibizumab. Photodynamic therapy with visudyne or laser photocoagulation or intravitreal steroids may be considered as monotherapy or in combination with Ranibizumab at the investigator's discretion if rescue criteria are met

    Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc

Interventions

  • Drugranibizumab 0.5 or 2.0 mg/0.05 cc

    Drug page: RanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups.

    Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure - related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

    Time frame: 2 years

Secondary outcomes

  1. Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months

    Time frame: 12 months

  2. Change in Mean Central Foveal Thickness From Baseline

    Time frame: 12 Months

  3. Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months

    Time frame: 12 Months

  4. Number of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters

    Time frame: 3 Months

  5. Number of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters

    Time frame: 6 months

  6. Number of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters

    Time frame: 9 Months

  7. Number of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters

    Time frame: 12 Months

  8. Mean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12

    Time frame: 12 months

  9. Number of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters

    Time frame: 3 months

  10. Number of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters

    Time frame: 6 months

  11. Number of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters

    Time frame: 9 months

  12. Number of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters

    Time frame: 12 months

07

Results

Posted Dec 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mg
Started155
Completed155
Not completed00

Outcome measures

PrimaryIncidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups.

Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure - related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

Time frame:
2 years
Reported as:
Number · Adverse events
Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups.
Adverse eventsControl Group: Ranibizumab 0.5mgRanibizumab 1.0mg or 2.0mg
Total Ocular and Notable Systemic AEs424
Blurred or decreased vision06
Floaters24
Dark Spots03
Injection site or ocular pain02
Increased Cataracts02
Subretinal hemorrhage01
Superior hemorrhage01
Increased Choroidal Neovascularization01
Corneal abrasion01
Trace epiretinal membrane01
Flashes01
Progression of edema01
Light sensitivity10
Elevated blood pressure10
Statistical analysis
  • Control Group: Ranibizumab 0.5mg vs Ranibizumab 1.0mg or 2.0mg · t-test, 2 sided · p = 0.05 (28 ocular and non-ocular adverse events collected, in mild to moderate nature) · Data survey: 28 · 95% CI 0 to 28
SecondaryMean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months
Time frame:
12 months
Reported as:
Mean · letters
Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months
lettersRanibizumab 2.0 mgRanibizumab 0.5 mg
Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months6.7 (-3 to 25)-5 (-25 to 9)
SecondaryChange in Mean Central Foveal Thickness From Baseline
Time frame:
12 Months
Reported as:
Mean · um
Change in Mean Central Foveal Thickness From Baseline
umRanibizumab 2.0 mgRanibizumab 0.5 mg
Change in Mean Central Foveal Thickness From Baseline-49.7 ± 100.7194.4 ± 89.6
SecondaryMean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months
Time frame:
12 Months
Reported as:
Mean · mm^2
Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months
mm^2Ranibizumab 2.0 mgRanibizumab 0.5 mg
Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months2.38 (-1.12 to 8.71)-0.38 (-1.12 to -0.02)
SecondaryNumber of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame:
3 Months
Reported as:
Count of participants · Participants
Number of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5-9 letters30
10-14 letters20
15 letters or more30
Less than 5 letters60
Unevaluable10
SecondaryNumber of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters31
10 letters10
15 or more letters40
SecondaryNumber of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame:
9 Months
Reported as:
Count of participants · Participants
Number of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters30
10 letters30
15 letters20
SecondaryNumber of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
Time frame:
12 Months
Reported as:
Count of participants · Participants
Number of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters41
10 letters10
15 letters30
SecondaryMean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12
Time frame:
12 months
Reported as:
Mean · letters
Mean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12
lettersRanibizumab 2.0 mgRanibizumab 0.5 mg
Mean Change Baseline - M39.87 ± 15.27-2.8 ± 32.71
Mean Change Baseline - M610.23 ± 33.51-3.6 ± 2.35
Mean Change Baseline - M910.93 ± 43.81-6.8 ± 9.08
Mean Change Baseline - M126.37 ± 26.02-7.3 ± 20.11
SecondaryNumber of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters10
10 letters00
15 letters11
SecondaryNumber of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters01
10 letters01
15 letters10
SecondaryNumber of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters00
10 letters00
15 letters11
SecondaryNumber of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters
ParticipantsRanibizumab 2.0 mgRanibizumab 0.5 mg
5 letters01
10 letters00
15 letters01

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group: Ranibizumab 0.5mg—0/5 (0%)2/5 (40%)
Ranibizumab 1.0mg or 2.0mg—0/15 (0%)9/15 (60%)
Most frequent other events
Most frequent other events
EventControl Group: Ranibizumab 0.5mgRanibizumab 1.0mg or 2.0mg
Affected visionEye disorders1/56/15
Elevated Blood pressureCardiac disorders1/50/15
Intravitreal injection side effectsEye disorders0/52/15
Increased cataractEye disorders0/52/15
Superior hemorrhageEye disorders0/51/15
Increased Choroidal neovascularizationEye disorders0/51/15
Corneal AbrasionEye disorders0/51/15
Trace epiretinal membraneEye disorders0/51/15
Progression of edemaCardiac disorders0/51/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mgTotal
<=18 years000
Between 18 and 65 years12416
>=65 years314
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mgTotal
Female729
Male8311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mgTotal
Hispanic or Latino000
Not Hispanic or Latino15520
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mgTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American718
White7411
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ranibizumab 1.0 or 2.0 mg (HIGH DOSE)Ranibizumab 0.5 mgTotal
United States15520
08

Study locations

1 site
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2022, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 10, 2011
Start
Sep 2011
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Dec 12, 2022
Last update
Dec 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01469156
Lead sponsor
Southeast Retina Center, Georgia
Collaborators
Genentech, Inc.
Responsible party
Dennis M. Marcus, M.D. (Dr. Dennis M. Marcus Principal Investigator, Southeast Retina Center, Georgia) — Principal investigator
First posted
Nov 10, 2011
Start date
Sep 2011
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Dec 12, 2022
Last update
Dec 12, 2022

Study contacts

Dennis M. Marcus, M.D.
principal investigator · Southeast Retina Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion